The benefit of running clinical trials in Asia-Pacific for biotech companies
According to Frost & Sullivan, the CRO market is forecast to grow to US$ 71.7billion by 2024 (+8% CAGR 19-24F).…
According to Frost & Sullivan, the CRO market is forecast to grow to US$ 71.7billion by 2024 (+8% CAGR 19-24F).…
The number of biotech-sponsored clinical trials in Australia has grown by more than +10% on average each year between 2017…
Asia-Pacific biotech specialist CRO Novotech has released a new webinar about the advantages of conducting oncology clinical trials in the…
There are more than 1,300 clinical trials in hepatology, either ongoing or planned, in Asia-Pacific. This represents about 60% of…
Many countries in the Asia-Pacific region are now fast-tracking their COVID-19 clients’ clinical trials with expedited review processes for treatment…
Novotech, the Asia-Pacific CRO, has published data detailing the current status of clinical trials in the Asia-Pacific region during the…
Due to its geographic proximity with China, South Korea was one of the first locations hit with the Covid-19 viral…
Business consulting firm Frost & Sullivan and Asia-Pacific CRO specialist Novotech published a report summarising the main trends and developments…
The alliance of regional specialists can provide the best of all worlds: global coverage, regional specialisation and mid-sized CRO flexibility.…
Clinical development in oncology and immunotherapies has accelerated dramatically over the past few years. As of December 2019, over 6,000…